Immatics Secures Four Oral Presentations at 2026 ASCO Annual Meeting for PRAME Pipeline

summarizeSummary

Immatics N.V. announced that all four of its submitted abstracts have been selected for oral presentations at the upcoming 2026 ASCO Annual Meeting, highlighting progress across its clinical cell therapy and bispecific portfolio.

check_boxKey Events

• ASCO Oral Presentations Secured

  Immatics will deliver four oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 29 to June 2, 2026.

• Broad Pipeline Showcase

  The presentations will cover updated Phase 1b clinical data for anzu-cel in melanoma, updated Phase 1a/1b data for IMA203CD8 in gynecologic cancers, Phase 1 data for PRAME cell therapies in synovial sarcoma, and updated results for the IMA401 bispecific across multiple cancers.

• Upcoming Abstract Release

  Full abstracts detailing the presentation content will be made available on the ASCO website on May 21, 2026.

auto_awesomeAnalysis

This announcement is highly significant for Immatics, a clinical-stage biotech company. Securing four oral presentation slots at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting provides a major platform to showcase the breadth and depth of its PRAME-directed pipeline. The presentations will include updated clinical data for its lead anzu-cel cell therapy, the second-generation IMA203CD8, PRAME cell therapies in synovial sarcoma, and the IMA401 bispecific. This level of visibility at ASCO can significantly boost investor confidence and attract attention to the company's therapeutic candidates, especially following the positive clinical data announced just days prior. Investors should monitor the full abstract release on May 21, 2026, and the presentations themselves for further insights into the data.